Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Failure to achieve target IOP leads to more rapid visual field worsening
Treated patients who fail to achieve the target intraocular pressure (IOP) are at higher odds of experiencing more rapid visual field (VF) worsening, reports a study. Those with moderate glaucoma have the greatest VF worsening from such failure.
Failure to achieve target IOP leads to more rapid visual field worsening
11 Jan 2022Cardiovascular drugs do not worsen COVID-19 outcomes
Use of cardiovascular medications does not lead to poor COVID-19 clinical outcomes among high-risk patients, such as those with hypertension, according to a study.
Cardiovascular drugs do not worsen COVID-19 outcomes
11 Jan 2022Old age, non-English language tied to incomplete telehealth visit
Older patients, non‒English-speaking individuals, and ethnic/racial minorities are less likely to complete a video telemedicine encounter for ophthalmic care during the COVID-19 pandemic, a study has found.
Old age, non-English language tied to incomplete telehealth visit
11 Jan 2022Intensive rehab benefits lung cancer patients undergoing surgery
A rehabilitation programme comprising intensive perioperative pulmonary rehabilitation (PR) and standard of care (SC) led to improved exercise capacity and tolerance in individuals with early-stage non-small-cell lung cancer (NSCLC) who are undergoing lung resection, the PUREAIR trial suggests.
Intensive rehab benefits lung cancer patients undergoing surgery
11 Jan 2022COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.
COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
11 Jan 2022Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.